Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Meeting ReportAnnual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Dermatologists’ Management of Psoriatic Arthritis: A Report from the 2014 GRAPPA Meeting

Wolf-Henning Boehncke
The Journal of Rheumatology June 2015, 42 (6) 1029-1031; DOI: https://doi.org/10.3899/jrheum.150125
Wolf-Henning Boehncke
From the Department of Dermatology, Geneva University Hospital, Geneva, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: wolf-henning.boehncke@hcuge.ch
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

The presence of concomitant psoriatic arthritis (PsA) directly affects the treatment decisions dermatologists may make as they manage their patients’ psoriasis (PsO). Because the prevalence of PsA increases with PsO duration, it is important to regularly screen for signs and symptoms of PsA. Dermatologists and rheumatologists agree that they need to cooperate in the management of skin and musculoskeletal manifestations of PsA. However, the respective healthcare systems substantially influence how this cooperation is achieved in different countries and possibly even within regions. Some models exist that address how this crucial cooperation can be achieved.

Key Indexing Terms:
  • PSORIASIS
  • PREVALENCE
  • DERMATOLOGIST
  • RHEUMATOLOGIST

According to current guidelines, mild psoriasis (PsO) can potentially be managed using topical therapies, while moderate-to-severe PsO necessitates phototherapy or systemic therapy in combination with topicals1. If the patient has coexisting psoriatic arthritis (PsA), a systemic therapy may be needed even if the patient exhibits only mild PsO2. Further, PsA may involve peripheral joints, the axial skeleton, tendons, and entheses3, all of which respond differently to drugs currently available4. The presence and type of PsA, therefore, may directly influence the dermatologist’s treatment decision. This is true from a medical as well as from a regulatory point of view, as not every drug available to treat PsO is approved for the treatment of both PsO and PsA, and vice versa.

The Role of Dermatologists in Screening for PsA

Along with the difficulties described above, dermatologists need to screen for PsA symptoms for at least 3 additional reasons5:

  1. PsA is more common than previously thought. While older textbooks cite PsA in 6–8% of patients with PsO, more recent epidemiologic and clinical studies suggest numbers on the order of 15–30%.

  2. PsA is more serious than previously thought. Although it has sometimes been nicknamed “the little sister of rheumatoid arthritis,” it is now clear that about 50% of patients with PsA have a chronic-progressive disease course.

  3. Even a relatively short delay in diagnosis and adequate treatment of PsA is associated with a worse longterm outcome6.

Thus, screening for PsA to ensure early diagnosis and treatment is a high priority. And dermatologists are in a position to be “sentinels,” because in the majority of cases, PsA symptoms manifest after the onset of PsO3.

Who and How to Screen

Although there is a trend toward a higher prevalence of PsA among patients with severe PsO, the prevalence of PsA among patients with mild PsO is still high, thus necessitating inclusion of every patient with PsO in the dermatologists’ screening efforts. The likelihood of PsA is particularly high if the patient has PsO of the scalp or nails, or has perianal or intertriginous manifestations7.

Given the clinical heterogeneity of PsA, it is difficult for nonrheumatologists to establish this diagnosis. Numerous groups have developed screening questionnaires as potential tools for this purpose, e.g., the Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire, the Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire, and the Psoriasis Epidemiology Screening Tool (PEST). While initial reports of these questionnaires suggested good sensitivities, a subsequent publication reported much lower ones8. In a recent head-to-head comparison study, sensitivity values of about 75% were found9. Such questionnaires — with reasonably good but not excellent sensitivity — might therefore be considered helpful for screening purposes, but should not replace careful physical examination and additional questions.

How to Organize the Cooperation Between Dermatologists and Rheumatologists

It is evident that screening for PsA is an important task for dermatologists, but it might quickly become time-consuming once actions beyond the evaluation of questionnaires are involved. The need to effectively and efficiently identify potential PsA patients for referral to a rheumatologist for diagnosis where required and to organize cooperation between dermatologists and rheumatologists for patients with PsA becomes even more urgent to ensure these patients are appropriately treated and monitored to improve longterm outcomes. Achieving this cooperation depends to a large extent on the resources made available by the respective healthcare system, as highlighted by a comparison between Germany and Switzerland.

Cooperation Between Dermatologists and Rheumatologists in Germany and Switzerland

The German and Swiss healthcare systems are comparable with regard to many key criteria including availability of drugs and strategies for reimbursement. To date, however, German and Swiss dermatologists and rheumatologists have not determined how to cooperate best with regard to managing patients with PsA.

In Germany, numerous initiatives over the last decade were meant to enable dermatologists to screen for and to a certain extent, to treat PsA. These included joint symposia of dermatologists and rheumatologists on the management of PsA as well as workshops focusing on the early diagnosis of PsA by dermatologists.

In Switzerland, a recent Delphi exercise in a group of 8 dermatologists and 8 rheumatologists from secondary and tertiary care centers yielded different answers from the 2 professions (Table 1)10. The group did agree on the importance of screening patients with PsO for signs and symptoms of PsA, as well as the potential for dermatologists to serve as sentinels in this regard. Moreover, they agreed on the goal to initiate an effective early treatment to prevent structural damage and functional loss.

View this table:
  • View inline
  • View popup
Table 1.

Summary of key statements resulting from a recent interdisciplinary Delphi exercise conducted in Switzerland (summarized from Boehncke, et al, Dermatology 2015;230:75–8110).

On the other hand, the rheumatologists discouraged a more active role for dermatologists. For example, the group agreed that nonrheumatologists should not order imaging as part of the diagnostic investigations, and initiation of a therapy with disease-modifying antirheumatic drugs such as methotrexate or biologics should be discussed with a rheumatologist.

With regard to the envisioned cooperative models, these differences may be explained at least in part by the differences in the respective healthcare systems despite numerous similarities11. In Germany, there are about 4000 dermatologists and 400 rheumatologists for 80 million people; in Switzerland, the respective numbers are 400, 400, and 8 million. Thus, German dermatologists need to serve as “filters” to protect the time of rheumatologists, while rheumatologists in Switzerland probably have time to see patients with PsA, those with other inflammatory joint diseases, and those with noninflammatory disorders such as osteoarthritis. Hence, the respective roles of dermatologists might be labeled “gatekeeper” in Germany, but “pilot” in Switzerland.

Perspectives

While the importance of PsO as a global health problem has been widely accepted and underlined by a recent resolution of the World Health Organization, awareness of the importance and effect of PsA must still be fully established. Routine screening for PsA among patients with PsO is not widely practiced, and the available tools must be optimized further. Even in developed countries, there is a shortage of resources dedicated to the adequate care of patients with PsA.

REFERENCES

  1. 1.↵
    1. Nast A,
    2. Boehncke W-H,
    3. Mrowietz U,
    4. Ockenfels HM,
    5. Philipp S,
    6. Reich K,
    7. et al.
    S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges 2012;10 Suppl 2:S1–95.
    OpenUrl
  2. 2.↵
    1. Gossec L,
    2. Smolen JS,
    3. Gaujoux-Viala C,
    4. Ash Z,
    5. Marzo-Ortega H,
    6. van der Heijde D,
    7. et al.
    European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4–12.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Gladman DD,
    2. Shuckett R,
    3. Russell ML,
    4. Thorne JC,
    5. Schachter RK
    . Psoriatic arthritis (PSA)—an analysis of 220 patients. Q J Med 1987;62:127–41.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Ritchlin CT,
    2. Kavanaugh A,
    3. Gladman DD,
    4. Mease PJ,
    5. Helliwell P,
    6. Boehncke W-H,
    7. et al.
    Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387–94.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Boehncke W-H,
    2. Kirby B,
    3. Fitzgerald O,
    4. van de Kerkhof PC
    . New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease. J Eur Acad Dermatol Venereol 2014;28:264–70.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Haroon M,
    2. Gallagher P,
    3. Fitzgerald O
    . Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis 2014 Feb 27 (E-pub ahead of print).
  7. 7.↵
    1. Wilson FC,
    2. Icen M,
    3. Crowson CS,
    4. McEvoy MT,
    5. Gabriel SE,
    6. Kremers HM
    . Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61:233–9.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Haroon M,
    2. Kirby B,
    3. FitzGerald O
    . High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis 2013;72:736–40.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Coates LC,
    2. Aslam T,
    3. Al Balushi F,
    4. Burden AD,
    5. Burden-Teh E,
    6. Caperon AR,
    7. et al.
    Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol 2013;168:802–7.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Boehncke W-H,
    2. Anliker MD,
    3. Conrad C,
    4. Dudler J,
    5. Hasler F,
    6. Hasler P,
    7. et al.
    The dermatologists’ role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists. Dermatology 2015;230:75–81.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Boehncke W-H,
    2. Menter A
    . Burden of disease: psoriasis and psoriatic arthritis. Am J Clin Dermatol 2013;14:377–88.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 42, Issue 6
1 Jun 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dermatologists’ Management of Psoriatic Arthritis: A Report from the 2014 GRAPPA Meeting
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Dermatologists’ Management of Psoriatic Arthritis: A Report from the 2014 GRAPPA Meeting
Wolf-Henning Boehncke
The Journal of Rheumatology Jun 2015, 42 (6) 1029-1031; DOI: 10.3899/jrheum.150125

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Dermatologists’ Management of Psoriatic Arthritis: A Report from the 2014 GRAPPA Meeting
Wolf-Henning Boehncke
The Journal of Rheumatology Jun 2015, 42 (6) 1029-1031; DOI: 10.3899/jrheum.150125
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • The Role of Dermatologists in Screening for PsA
    • Who and How to Screen
    • How to Organize the Cooperation Between Dermatologists and Rheumatologists
    • Cooperation Between Dermatologists and Rheumatologists in Germany and Switzerland
    • Perspectives
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

PSORIASIS
PREVALENCE
DERMATOLOGIST
RHEUMATOLOGIST

Related Articles

Cited By...

More in this TOC Section

  • The Psoriasis Symptom Inventory: An Effective Patient-reported Outcome Measure of Psoriasis Severity
  • Utility in Clinical Trials of Magnetic Resonance Imaging for Psoriatic Arthritis: A Report from the GRAPPA 2014 Annual Meeting
  • GRAPPA Treatment Recommendations: An Update from the GRAPPA 2014 Annual Meeting and GRAPPA Meeting Adjacent to the 2014 ACR Meeting
Show more Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

Similar Articles

Keywords

  • psoriasis
  • prevalence
  • DERMATOLOGIST
  • RHEUMATOLOGIST

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire